CardioMech Raises $18.5M in Series A Funding


CardioMech AS, a Trondheim, Norway-based medical device company developing a transfemoral, transseptally delivered mitral valve repair technology, raised $18.5m in Series A financing.

The round was led by a non-disclosed strategic investor together with healthcare specialist investor Hadean Ventures and Investinor.

The company intends to use the funds to conduct its first-in-human feasibility trial.

Led by Rick Nehm, President and CEO, CardioMech is developing a catheter-based mitral valve repair technology as an alternative to open-heart cardiac surgery by placing its artificial chord(s) in the heart via a catheter to reduce or eliminate mitral regurgitation without opening the chest, stopping the heart, or going on heart-lung bypass.



Join the discussion